Optiscan Imaging completes key milestone in digital study
- Optiscan imaged more than 80 digital pathology cases.
- Optiscan's share price remained unchanged at $0.16 following the update.
- The trials aim to support future regulatory submissions.
Optiscan Imaging (ASX:OIL) imaged over 80 cases using its InForm platform in a live digital pathology study conducted with Australian Clinical Labs (ASX:ACL).
The clinical trials build upon previous laboratory testing by evaluating point-of-contact cellular imaging across various tissue types and cancers.
The study is taking place within Australian Clinical Labs' flagship anatomical pathology laboratory located in Western Australia.
ACL Clinical Director Dr Marissa Muller said, "Reaching more than 80 cases in this study marks an important milestone in our collaboration with Optiscan and reflects ACL’s commitment to innovation that has the potential to deliver meaningful benefits for patients, pathologists and laboratory teams.”
The company stated that data gathered from the study will support workflow optimisation, pathologist training, and future regulatory submissions.
Following the announcement, the Optiscan Imaging share price was unchanged at $0.16.
The trial leverages Australian Clinical Labs' extensive pathology network to validate real-time imaging technology.
Optiscan continues to focus on developing slide-free microscopic imaging tools for medical applications.
